The FDA announced a phaseout of animal testing, a move involving Certara and referencing the background of a CEO formerly with DuPont.
2 reports, 1 independent
Updated Aug 8
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA announced a phaseout of animal testing, a move involving Certara and referencing the background of a CEO formerly with DuPont.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA begins phasing out animal testing, involving Certara and DuPont connections.1 source
FDA animal testing phaseout impacts Certara; financial developments include Morgan Stanley rating and ChemAxon revenue contribution.1 source
Keep exploring
The entities involved
- FDA
-
Certara (United States)
company in St Louis, United States
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyCertara, Inc. (CERT): A Bull Case Theory We came across a bullish thesis on Certara, Inc. on Stock Picker's Journey’s Substack by Gregg Jahnke. In this article, we will summarize the bulls’ thesis on
- Insider MonkeyMorgan Stanley Assumes Coverage of Certara (CERT) Stock Certara, Inc. (NASDAQ:CERT) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Morgan Stanley assumed coverage of